Kelun Pharma
![ASCO 2023:Kelun Pharma’s SKB264 shows early signs of potential in NSCLC patients](https://pharmtales.com/wp-content/uploads/2023/06/ASCO-2023Kelun-Pharmas-SKB264-shows-early-signs-of-potential-in-NSCLC-patients.jpg)
ASCO 2023:Kelun Pharma’s SKB264 shows early signs of potential in NSCLC patients
SG Tylor
ABSTRACT NUMBER – 9114 SKB264 is an innovative anti-TROP2 ADC that specifically targets a poor prognosis marker found in 70% ...
ABSTRACT NUMBER – 9114 SKB264 is an innovative anti-TROP2 ADC that specifically targets a poor prognosis marker found in 70% ...